Work

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.4762.4762

Authors: Saad Z. Usmani, Rachael Sexton, Sikander Ailawadhi, Jatin J. Shah, Natalie S Callander, Todd Zimmerman, Jason Valent, Michael Rosenzweig, Brea C. Lipe, Jeffrey Zonder, Sandi Fredette, Brian G. M. Durie, Antje Hoering, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski

Institutions: Levine Cancer Institute, Cancer Research And Biostatistics, Mayo Clinic in Florida, The University of Texas MD Anderson Cancer Center, University of Wisconsin–Madison, William S. Middleton Memorial Veterans Hospital, University of Chicago, Cleveland Clinic, City Of Hope National Medical Center, City of Hope, University of Kansas Medical Center, The Barbara Ann Karmanos Cancer Institute, SWOG Cancer Research Network, Cedars-Sinai Medical Center, Mayo Clinic, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2514747439

FWCI: 0.612

Cites:

Cited by: 5

Related to: 10